New immunotherapy combo tested in kids with Hard-to-Treat cancers

NCT ID NCT03837899

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This study is testing two immunotherapy drugs, durvalumab and tremelimumab, in children and teens up to age 17 with advanced solid tumors or blood cancers that have not responded to standard treatments. The first part finds the safest dose, and the second part checks if the drugs can shrink tumors. The goal is to control the disease, not cure it, as ongoing treatment may be needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anaplastic large cell lymphoma childhood malignant neoplasm childhood neoplasm hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm neoplasm non-Hodgkin lymphoma primary mediastinal large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGICAL MALIGNANCIES PEDIATRIC CANCER SOLID TUMOR PEDIATRIC

Contacts and locations

Locations

Research Site

Baltimore, Maryland, 21231, United States
Research Site

Boston, Massachusetts, 02115, United States
Research Site

New Hyde Park, New York, 11040, United States
Research Site

Oklahoma City, Oklahoma, 73104, United States
Research Site

Charleston, South Carolina, 29425, United States
Research Site

Lille, 59020, France
Research Site

Marseille, 13385, France
Research Site

Paris, 75248, France
Research Site

Cologne, 50924, Germany
Research Site

Genova, 16100, Italy
Research Site

Milan, 20133, Italy
Research Site

Rome, 00165, Italy
Research Site

Torino, 10126, Italy
Research Site

Utrecht, 3584 CS, Netherlands
Research Site

Barcelona, 08035, Spain
Research Site

Madrid, 28009, Spain
Research Site

Leeds, LS1 3EX, United Kingdom
Research Site

London, WC1N 3JH, United Kingdom
Research Site

Sutton, SM2 5PT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.